GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » YoY EPS Growth

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) YoY EPS Growth : 0.00% (As of Dec. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Eucrates Biomedical Acquisition's YoY EPS Growth for the quarter that ended in Dec. 2022 was 0.00%.

Eucrates Biomedical Acquisition's Earnings per Share (Diluted) for the three months ended in Dec. 2022 was $0.00.

Eucrates Biomedical Acquisition YoY EPS Growth Historical Data

The historical data trend for Eucrates Biomedical Acquisition's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition YoY EPS Growth Chart

Eucrates Biomedical Acquisition Annual Data
Trend Dec20 Dec21 Dec22
YoY EPS Growth
- - -

Eucrates Biomedical Acquisition Quarterly Data
Aug20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eucrates Biomedical Acquisition YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Eucrates Biomedical Acquisition's YoY EPS Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EPS Growth (A: Dec. 2022 )
=(Earnings per Share (Diluted) (A: Dec. 2022 )-Earnings per Share (Diluted) (A: Dec. 2021 ))/ | Earnings per Share (Diluted) (A: Dec. 2021 ) |
=(0-0)/ | 0 |
=N/A %

Eucrates Biomedical Acquisition's YoY EPS Growth for the quarter that ended in Dec. 2022 is calculated as:

YoY EPS Growth (Q: Dec. 2022 )
=(Earnings per Share (Diluted) (Q: Dec. 2022 )-Earnings per Share (Diluted) (Q: Dec. 2021 )) / | Earnings per Share (Diluted) (Q: Dec. 2021 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eucrates Biomedical Acquisition YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » YoY EPS Growth
Comparable Companies
FXCO AEHA LMAO AOGO GLEE ENCP JMAC VSAC OTRA OTEC GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Website
Eucrates Biomedical Acquisition Corp is a blank check company.
Executives
Stelios Papadopoulos director, 10 percent owner 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell director 270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro director 2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena director, 10 percent owner, officer: Chief Executive Officer 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal officer: Vice President 250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova officer: Chief Financial Officer 250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe officer: Senior Vice President C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis director, officer: President, COO C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal director C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines

From GuruFocus

Eucrates Biomedical Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 06-01-2021

Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering

By PRNewswire PRNewswire • 10-28-2020

Eucrates Biomedical Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 04-11-2023